SC 13D/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

 

 

Sucampo Pharmaceuticals, Inc.

(Name of Issuer)

Class A Common Stock, par value $0.01

(Title of Class of Securities)

864909106

(CUSIP Number)

David N. Oakey, Esquire

McGuireWoods LLP

800 East Canal Street

Richmond, VA 23219

(804) 775-1022

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

June 12, 2017

(Date of event which requires filing of this statement)

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because § 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g) check the following box  ☐.

 

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

 

 

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

 

 

 


  1   

NAMES OF REPORTING PERSONS.

Sachiko Kuno

 

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).

  2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)  ☐        (b)  ☐

 

  3  

SEC USE ONLY

 

  4  

SOURCE OF FUNDS

 

OO

  5  

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)  ☐

 

  6  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

United States

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 

     7    

SOLE VOTING POWER

 

8,353,204(1)

     8   

SHARED VOTING POWER

 

0

     9   

SOLE DISPOSITIVE POWER

 

8,353,204(1)

   10   

SHARED DISPOSITIVE POWER

 

0

11  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

8,353,204(1)

12  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  ☐

 

13  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

 

17.9%

14  

TYPE OF REPORTING PERSON

 

IN

 

(1)  Includes 1,215,860 shares held by Sachiko Kuno Foundation, Inc., a nonstock corporation for which the reporting person currently serves as the sole director (the “Foundation”). The reporting person disclaims beneficial ownership of the shares held by the Foundation.


  1   

NAMES OF REPORTING PERSONS.

SK Impact Fund, LLC

 

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).

47-4914300

  2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)  ☐        (b)  ☐

 

  3  

SEC USE ONLY

 

  4  

SOURCE OF FUNDS

 

OO

  5  

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)  ☐

 

  6  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

District of Columbia

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 

     7    

SOLE VOTING POWER

 

7,137,344

     8   

SHARED VOTING POWER

 

0

     9   

SOLE DISPOSITIVE POWER

 

7,137,344

   10   

SHARED DISPOSITIVE POWER

 

0

11  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

7,137,344

12  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  ☐

 

13  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

 

15.3%

14  

TYPE OF REPORTING PERSON

 

OO


Explanatory Note: This Amendment No. 1 amends and supplements the Schedule 13D originally filed by the undersigned with the Securities and Exchange Commission on December 29, 2016 (the “Original Filing”). Capitalized terms used in this Amendment No. 1 and not defined herein have the respective meanings assigned to such terms in the Schedule 13D.

Item 4. Purpose of Transaction.

Item 4 is hereby amended and restated as follows:

The Reporting Persons have no present plans or proposals which relate to, or would result in, any one or more of the matters described in subparagraphs (a) through (j) of Item 4 of Schedule 13D, but do reserve the right to, from time to time, acquire or dispose of Shares.

Given its status as a significant shareholder, representatives of the LLC may, from time to time, engage in discussions with the Issuer regarding the Issuer’s corporate strategy and general business activities.

Item 5. Interest in Securities of the Issuer.

Item 5 is hereby amended and restated as follows:

 

  (a) The number and percentage of Shares beneficially owned by the Reporting Persons is provided in Items 11 and 13 of each of their respective Cover Pages and is incorporated herein by reference. The beneficial ownership percentage reflected on each Cover Page is based on the total number of Shares reported as outstanding in the Quarterly Report on Form 10-Q filed by the Issuer with the Securities and Exchange Commission on August 2, 2017. The number and percentage of Shares beneficially owned by the Listed Persons is set forth on Schedule A and is incorporated herein by reference.

Dr. Kuno is the indirect beneficial owner of the 7,137,344 Shares held by the LLC. Dr. Kuno may also be deemed to be the indirect beneficial owner of the 1,215,860 Shares held by the Foundation. Dr. Kuno, however, disclaims beneficial ownership of the Shares held by the Foundation.

 

  (b) The nature of the Reporting Persons’ voting and dispositive power with regard to the Shares described in Item 5(a) above is reflected in Items 7 through 10 of each of their respective Cover Pages, which information is incorporated herein by reference. The nature of the Listed Person’s beneficial ownership of Shares is set forth on Schedule A and is incorporated herein by reference.

 

  (c) On September 11, 2017, the LLC sold 1,000,000 Shares for $12.00 per share through a block trade pursuant to Rule 144 under the Securities Act of 1933, as amended. Transactions engaged in by the Foundation since the Original Filing are listed on Schedule B and incorporated herein by reference. The Reporting Persons have otherwise engaged in no transactions since the Original Filing. Any transactions engaged in by the Listed Persons since the Original Filing are described on Schedule A and incorporated herein by reference.

 

  (d) Not applicable.

 

  (e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

Item 6 is hereby amended and restated as follows:

Not applicable.

Item 7. Material to be Filed as Exhibits.

Item 7 is hereby amended to delete Exhibit 1.2.


SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: September 27, 2017

 

/s/ Sachiko Kuno                                    
Sachiko Kuno

 

SK IMPACT FUND, LLC
By:  

/s/ Sachiko Kuno

Name:   Sachiko Kuno
Title:   Manager


Schedule A

 

Name

  

Position and Present Principal Occupation

   Shares Beneficially
Owned
Kei Tolliver   

Secretary and Treasurer, SK Impact Fund, LLC

Founder, Kei S. Tolliver Law, LLC

   1,8001

Ms. Tolliver is a citizen of Japan.

The principal business address for Ms. Tolliver is 2001 L Street, NW, Suite 750, Washington, DC 20036.

 

  1. Represents less than 1% of the outstanding Shares. All 1,800 Shares are held directly by Ms. Tolliver.

Ms. Tolliver has not engaged in any transactions in Shares since the Original Filing.


Schedule B

 

Reporting Person

 

Date

 

Transaction

 

Number of Shares

 

Price Per Share

 

Nature of Transaction

Dr. Sachiko Kuno1   09/01/2017   Sale   19,533   $11.8178   Open market sale
Dr. Sachiko Kuno1   08/31/2017   Sale   19,200   $11.6202   Open market sale
Dr. Sachiko Kuno1   08/30/2017   Sale   19,540   $11.4561   Open market sale
Dr. Sachiko Kuno1   08/29/2017   Sale   16,300   $11.3333   Open market sale
Dr. Sachiko Kuno1   08/28/2017   Sale   16,920   $11.3378   Open market sale
Dr. Sachiko Kuno1   08/25/2017   Sale   28,000   $11.2786   Open market sale
Dr. Sachiko Kuno1   08/24/2017   Sale   17,000   $11.2094   Open market sale
Dr. Sachiko Kuno1   08/23/2017   Sale   17,028   $11.2172   Open market sale
Dr. Sachiko Kuno1   08/22/2017   Sale   32,436   $11.1079   Open market sale
Dr. Sachiko Kuno1   08/21/2017   Sale   77,842   $11.0206   Open market sale
Dr. Sachiko Kuno1   08/16/2017   Sale   2,000   $10.5125   Open market sale
Dr. Sachiko Kuno1   08/15/2017   Sale   3,488   $10.5022   Open market sale
Dr. Sachiko Kuno1   08/14/2017   Sale   1,601   $10.5125   Open market sale
Dr. Sachiko Kuno1   08/09/2017   Sale   18,200   $10.6007   Open market sale
Dr. Sachiko Kuno1   08/08/2017   Sale   25,102   $10.6345   Open market sale
Dr. Sachiko Kuno1   08/07/2017   Sale   2,900   $10.5000   Open market sale
Dr. Sachiko Kuno1   08/04/2017   Sale   15,168   $10.5450   Open market sale
Dr. Sachiko Kuno1   08/03/2017   Sale   1,962   $10.5300   Open market sale
Dr. Sachiko Kuno1   08/02/2017   Sale   7,220   $10.7098   Open market sale
Dr. Sachiko Kuno1   08/01/2017   Sale   18,716   $10.6725   Open market sale
Dr. Sachiko Kuno1   07/31/2017   Sale   9,400   $10.8024   Open market sale
Dr. Sachiko Kuno1   07/28/2017   Sale   15,800   $10.8419   Open market sale
Dr. Sachiko Kuno1   07/27/2017   Sale   26,805   $10.7892   Open market sale
Dr. Sachiko Kuno1   07/26/2017   Sale   12,315   $11.0267   Open market sale
Dr. Sachiko Kuno1   07/25/2017   Sale   13,476   $11.0048   Open market sale
Dr. Sachiko Kuno1   07/24/2017   Sale   10,315   $10.9452   Open market sale
Dr. Sachiko Kuno1   07/21/2017   Sale   7,090   $10.9073   Open market sale
Dr. Sachiko Kuno1   07/20/2017   Sale   15,900   $10.9566   Open market sale
Dr. Sachiko Kuno1   07/19/2017   Sale   20,827   $10.8519   Open market sale
Dr. Sachiko Kuno1   07/18/2017   Sale   13,100   $10.8721   Open market sale
Dr. Sachiko Kuno1   07/17/2017   Sale   19,900   $10.9671   Open market sale
Dr. Sachiko Kuno1   07/14/2017   Sale   23,778   $11.0110   Open market sale
Dr. Sachiko Kuno1   07/13/2017   Sale   19,074   $10.9346   Open market sale
Dr. Sachiko Kuno1   07/12/2017   Sale   18,276   $10.7834   Open market sale
Dr. Sachiko Kuno1   07/11/2017   Sale   31,400   $10.7688   Open market sale
Dr. Sachiko Kuno1   07/10/2017   Sale   20,300   $10.7116   Open market sale
Dr. Sachiko Kuno1   07/07/2017   Sale   10,541   $10.6285   Open market sale
Dr. Sachiko Kuno1   07/06/2017   Sale   6,800   $10.5408   Open market sale
Dr. Sachiko Kuno1   07/05/2017   Sale   17,884   $10.6043   Open market sale
Dr. Sachiko Kuno1   07/03/2017   Sale   8,105   $10.6249   Open market sale
Dr. Sachiko Kuno1   06/30/2017   Sale   4,100   $10.5244   Open market sale
Dr. Sachiko Kuno1   06/29/2017   Sale   11,266   $10.5576   Open market sale
Dr. Sachiko Kuno1   06/28/2017   Sale   7,430   $10.5831   Open market sale
Dr. Sachiko Kuno1   06/27/2017   Sale   10,700   $10.4925   Open market sale
Dr. Sachiko Kuno1   06/12/2017   Sale   7,900   $10.0206   Open market sale
Dr. Sachiko Kuno1   06/09/2017   Sale   16,120   $10.1489   Open market sale
Dr. Sachiko Kuno1   06/08/2017   Sale   8,590   $10.0725   Open market sale
Dr. Sachiko Kuno1   06/07/2017   Sale   8,337   $10.0293   Open market sale
Dr. Sachiko Kuno1   06/06/2017   Sale   14,805   $10.0570   Open market sale
Dr. Sachiko Kuno1   06/05/2017   Sale   18,724   $10.0340   Open market sale
Dr. Sachiko Kuno1   06/02/2017   Sale   11,859   $10.3527   Open market sale
Dr. Sachiko Kuno1   05/30/2017   Sale   59,303   $10.0496   Open market sale
Dr. Sachiko Kuno1   05/26/2017   Sale   25,019   $10.2931   Open market sale
Dr. Sachiko Kuno1   05/25/2017   Sale   45,000   $10.4356   Open market sale
Dr. Sachiko Kuno1   05/24/2017   Sale   180,283   $10.6696   Open market sale
Dr. Sachiko Kuno1   05/23/2017   Sale   73,745   $10.4944   Open market sale

 

1. Shares held by the Foundation, for which the reporting person currently serves as the sole director. The reporting person disclaims beneficial ownership of shares held by the Foundation.